TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05340803

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonograghic optic nerve sheath diameter US-ONSD
Description: To compare effect of sedation in 3 groups by follow up of intracranial pressure by US-ONSD

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonograghic optic nerve sheath diameter US-ONSD
Description: To compare effect of sedation in 3 groups by follow up of intracranial pressure by US-ONSD

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonograghic optic nerve sheath diameter US-ONSD
Description: To compare effect of sedation in 3 groups by follow up of intracranial pressure by US-ONSD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: midazolam
Study: NCT05531435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de l'Appentière, Mazières-en-Mauges, France).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de l'Appentière, Mazières-en-Mauges, France).
Study: NCT05340803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: midazolam
Study: NCT06415422

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological samples
Description: Biological samples are taken from the patient's catheter inserted upon admission (the usual access route for patients): A daily sample is collected into a dry tube for off-site analysis by VeriFyNow until platelet function normalizes (for example, if platelet function normalizes on Day 2, no further VeriFyNow analysis will be conducted on subsequent days).
Study: NCT05048628

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparıson
Description: Only evaluation will be made at 0, 4, 6, and 8 hours after surgery without intervention in the control group.~For other groups; Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 4th, 6th, and 8th hours after the surgery and the resulting pain and hoarseness will be evaluated.
Study: NCT05340803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate
Description: magnesium sulfate
Study: NCT05048628

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparıson
Description: Only evaluation will be made at 0, 4, 6, and 8 hours after surgery without intervention in the control group.~For other groups; Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 4th, 6th, and 8th hours after the surgery and the resulting pain and hoarseness will be evaluated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparıson
Description: Only evaluation will be made at 0, 4, 6, and 8 hours after surgery without intervention in the control group.~For other groups; Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 4th, 6th, and 8th hours after the surgery and the resulting pain and hoarseness will be evaluated.
Study: NCT06131008

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diastology
Description: We will follow American Society of Echocardiography criteria to determine the degree of diastolic dysfunction after performing each focused echocardiogram.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diastology
Description: We will follow American Society of Echocardiography criteria to determine the degree of diastolic dysfunction after performing each focused echocardiogram.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diastology-Guided Diuresis
Description: If the daily urine output or weight loss are less than study-specified targets, then the research team will recommend changes to the diuretic regimen based on the degree of diastolic dysfunction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Clinicians will rely on usual care metrics and parameters to guide diuresis.
Study: NCT01629420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109
Study: NCT05831566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/Formoterol fumarate dihydrate
Description: The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months.~It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol fumarate dihydrate
Description: The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months.~It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders.
Study: NCT05851898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg
Description: Duloxetine 30mg daily prescribed at discharge
Study: NCT05477108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (BGF MDI HFO with oral activated charcoal)
Description: Subject will receive 4 inhalations as a single dose with oral activated charcoal - test formulation; administered during 1 Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (BGF MDI HFO with oral activated charcoal)
Description: Subject will receive 4 inhalations as a single dose with oral activated charcoal - test formulation; administered during 1 Treatment Period.
Study: NCT05928754

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: care strategy
Description: Uveitis patients:~* Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection;~* Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection;~* Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort);~* Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: care strategy
Description: Uveitis patients:~* Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection;~* Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection;~* Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort);~* Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7.
Study: NCT04927468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supramaximal rectus recession
Description: inferior rectus recession is 10mm，medial rectus recession is 9mm,superior rectus recession is 14mm for large-angle strabismus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: normal rectus recession
Description: inferior rectus recession is 7mm，medial rectus recession is 7mm,superior rectus recession is 7mm for large-angle strabismus
Study: NCT05825404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Ambient Bright Light (SABL)
Description: The Proposed Smart Ambient Bright Light (SABL) includes tunable LED lights, photosensors, and controllers. The SABL will provide bright light targeted at 400 lux and CS=0.3 in participant bedrooms and designated areas such as the dining room and activity room during the day and provide dim light ≤40 lux and CS≤0.1 in participant bedrooms at night

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Usual light.
Study: NCT06273046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Three visits will be made throughout the study. The first visit (Day -14) will consist of an evaluation of the inclusion criteria. A pre-treatment anorectal manometry will be performed, and a daily symptom questionnaire will be given to the patient. The second visit will take place 14 days later (Day 0). During this visit, the daily clinical symptom questionnaire will be collected and it will be verified that the patient meets the inclusion criteria. Patients who meet the criteria will be randomized 2:1 to active treatment or placebo. Patients will receive instructions, by means of psychoeducational videos on the exercises to be performed daily at home. A final visit will be performed at the end of the study (3 months in incontinence studies and 4 weeks in dyssynergic defecation studies). In incontinence study a final phone call will be performed at 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three visits will be made throughout the study following the same procedure as patients in the active arm. Patients randomized to placebo treatment will receive instructions to take a pill of placebo containing 0.3 g glucose daily at home. A final visit will be performed at the end of the study alike the active treatment group.
Study: NCT06104956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFNO weaning protocol
Description: Algorithm based on SpO2 values and respiratory rate: a decrease of FiO2 and of the flow will be done

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Weaning methods will be left to the free choice of the practitioner.
Study: NCT06507124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: This is observational with no intervention
Description: This is observational with no intervention
Study: NCT05737719

Intervention type: BEHAVIORAL
Intervention: Rehabilitation before knee surgery (prehab)
Description: Physiotherapy strategies for preparing the patient awaiting the surgical procedure

Intervention type: BEHAVIORAL
Intervention: Post-surgery rehabilitation
Description: Physiotherapy strategies to manage post-surgery recovery

Intervention type: BEHAVIORAL
Intervention: Post-surgery rehabilitation
Description: Physiotherapy strategies to manage post-surgery recovery
Study: NCT05583994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optim Park Intervention
Description: For participants receiving the Optim-Park II intervention, the aim is to enhance the process of living with Parkinson's Disease for the person with PD and the family-carer by building a multisectoral care pathway, with a special focus on how to optimize the use of resources and systems of support in the community in disadvantaged populations in UK.
Study: NCT06429189

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Home-based combined exercise program with self-selected intensity
Description: Before the beginning of the exercise program, participants will receive an education session on how to use Borg's Perceived Rate of Exertion Scale (RPE) to monitor their effort during aerobic and resistance training and tips on when they may increase the exercise intensity. During the training sessions, participants in the intervention group will be asked to choose their preferred load to execute each exercise in the resistance component, told to perform the aerobic exercises at their preferred speed, and informed that they can stop exercising whenever they need to rest. The exercise professional may suggest increasing loads in specific exercises, but these increases will not be imposed on the participants. Attendance to the sessions in the intervention and control groups will be registered. Additionally, women in this group will be encouraged to perform brisk walking at their preferred intensity and receive a pedometer to increase walking motivation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based combined exercise program with self-selected intensity
Description: Before the beginning of the exercise program, participants will receive an education session on how to use Borg's Perceived Rate of Exertion Scale (RPE) to monitor their effort during aerobic and resistance training and tips on when they may increase the exercise intensity. During the training sessions, participants in the intervention group will be asked to choose their preferred load to execute each exercise in the resistance component, told to perform the aerobic exercises at their preferred speed, and informed that they can stop exercising whenever they need to rest. The exercise professional may suggest increasing loads in specific exercises, but these increases will not be imposed on the participants. Attendance to the sessions in the intervention and control groups will be registered. Additionally, women in this group will be encouraged to perform brisk walking at their preferred intensity and receive a pedometer to increase walking motivation.
Study: NCT05477108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (BGF MDI HFA with oral activated charcoal)
Description: Subject will received 4 inhalations as a single dose with oral activated charcoal - reference formulation; administered during 2 Treatment Periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (BGF MDI HFA with oral activated charcoal)
Description: Subject will received 4 inhalations as a single dose with oral activated charcoal - reference formulation; administered during 2 Treatment Periods.
Study: NCT06277089

Intervention type: OTHER
Group type: OTHER
Intervention: Casts
Description: According to level of scoliosis cast done and recast in a serial manner
Study: NCT05069766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioXmark™
Description: During a scheduled outpatient gastroscopy, the tumor margins will be endoscopically marked by BioXmark™. BioXmark™ will be implanted at the most proximal margin of the tumor and 5 cm proximally of the tumor border.
Study: NCT04877379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: β-lactamase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: β-lactamase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: β-lactamase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: β-lactamase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5024 (ceftibuten)
Description: β-lactam antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5024 (ceftibuten)
Description: β-lactam antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5024 (ceftibuten)
Description: β-lactam antibiotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04829565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Description: echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of botulinum toxin 50 IU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of placebo
Study: NCT05070065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive remedy intervention with virtual reality (CEREBRUM)
Description: Cognitive Remedial method Virtual Reality (CEREBRUM)

Intervention type: DEVICE
Group type: OTHER
Intervention: Cognitive remedy intervention with virtual reality (CEREBRUM)
Description: Cognitive Remedial method Virtual Reality (CEREBRUM)
Study: NCT05435079

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-flow oxygen therapy device for tracheotomized patients
Description: From the output end of the automatic pressure-adjustable oxygen flow meter, connect the oxygen suction tube, Venturi, Fisher \& Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, closed sputum suction tube and tracheostomy tube), Adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy tube at 37°C according to the feedback temperature, and adjusts the oxygen therapy device according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow oxygen therapy device for tracheotomized patients
Description: From the output end of the automatic pressure-adjustable oxygen flow meter, connect the oxygen suction tube, Venturi, Fisher \& Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, closed sputum suction tube and tracheostomy tube), Adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy tube at 37°C according to the feedback temperature, and adjusts the oxygen therapy device according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.
Study: NCT05155007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilematovir
Description: Rilematovir will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilematovir
Description: Rilematovir will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilematovir
Description: Rilematovir will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilematovir
Description: Rilematovir will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilematovir
Description: Rilematovir will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilematovir
Description: Rilematovir will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin will be administered orally as per assigned treatment sequence.
Study: NCT04892043

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SQZ-AAC-HPV
Description: Activating antigen carriers (AACs) cell therapy; therapeutic vaccine engineered from red blood cells manufactured with immunogenic epitopes of HPV16

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SQZ-AAC-HPV
Description: Activating antigen carriers (AACs) cell therapy; therapeutic vaccine engineered from red blood cells manufactured with immunogenic epitopes of HPV16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Programmed cell death 1 (PD-1) blocking antibody
Study: NCT04727229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Injection of Bupivacaine near the stellate ganglion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Injection of Normal Saline near the stellate ganglion
Study: NCT05494242

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical intervention
Description: Pars-plana vitrectomy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Description: Pars-plana vitrectomy.
Study: NCT05799807

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Patients with negativ weight-bearing CT will be treated conservative

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive stabilization
Description: Patients with positive weight-bearing CT will be operated by minimally invasive stabilization (eg, isolated homerun screw)
Study: NCT06340646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Return of Genetic Results: Biomarker information from cancer cells
Description: Participants will receive a novel return of results report that is tailored to their choices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Return of Genetic Results: Inherited mutations related to cancer
Description: Participants will receive a novel return of results report that is tailored to their choices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Return of Genetic Results: Inherited mutations related to other medical issues
Description: Participants will receive a novel return of results report that is tailored to their choices.
Study: NCT04777708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nanoplexed Poly I:C BO-112
Description: Given by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV